马立巴韦|T2162

Maribavir
176161-24-3

￥769 1mg 起订

￥1120 2mg 起订

￥1830 5mg 起订

上海更新日期：2024-09-14

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 马立巴韦

英文名称：: Maribavir

CAS号：: 176161-24-3

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.85%

产品类别：: 抑制剂

货号：: T2162

Product Introduction

Bioactivity

名称	Maribavir
描述	Maribavir (GW257406X) is an orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of the viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents.
细胞实验	Maribavir (1263W94) is dissolved in DMSO and stored, and then diluted with appropriate media before use[2]. For these studies MRC-5 cells are seeded in 24-well plates at ~5×104 cells/well and grown for 3 days in MEM 8-1-1 to confluence (~1.1×105 cells/well). The cells are infected with AD169 in MEM 2-1-1 at an MOI ranging from 1 to 3 and incubated at 37°C for 90 min to allow viral adsorption. The unadsorbed virus is removed and replaced with 1 mL of MEM 2-1-1. To test the effect of compounds on viral DNA synthesis or maturation, Maribavir, BDCRB, or GCV is added to the medium at the concentrations indicated for each experiment[2].
激酶实验	Enzyme kinetic analysis is performed on the purified wild type and mutant UL97 protein species using increasing concentrations of ATP (2 μM to 20 μM). The amount of incorporated radiolabelled phosphate is plotted against the concentration of ATP in a Lineweaver Burke plot to determine the Km for ATP for each UL97 species. The effect of Maribavir upon the rate of radiolabelled phosphate incorporation by wild type or mutant UL97 is determined by protein kinase assays at a fixed concentration of Maribavir (0.5 μM) as above, or with increasing concentrations of Maribavir (0.01 μM to 5.0 μM) to determine the IC50 of Maribavir for each UL97 species. In order to determine the nature of the inhibition mediated by Maribavir, plots of 1/v vs 1/ATP with increasing concentrations of Maribavir are constructed. Competitive inhibition is evident if the family of lines cconverged on the y-axis at 1/Vmax. The change in slope caused by the addition of Maribavir is used to calculate the Ki[1].
体外活性	Maribavir是一种强效的抑制剂，能够有效抑制野生型及所有主要的Ganciclovir（GCV）耐药UL97突变体的自磷酸化，平均IC50值为35 nM。M460I突变体对Maribavir表现出超敏感性，IC50值为4.8 nM。Maribavir耐药的UL97突变体（L397R）在功能上受到损害，无论作为Ganciclovir激酶还是蛋白激酶的表现都大大降低（约为野生型的10%）。酶动力学实验表明，Maribavir是ATP的竞争性抑制剂，Ki值为10 nM[1]。Maribavir（1263W94）能够以剂量依赖的方式抑制病毒复制，通过多周期DNA杂交分析测得的IC50为0.12±0.01 μM。pUL97蛋白激酶被Maribavir强烈抑制，50%抑制浓度为3 nM[2]。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 60 mg/mL (159.47 mM)
关键字	inhibit \| Cytomegalovirus \| CMV \| Inhibitor \| Maribavir
相关产品	Resiquimod \| RO8191 \| Honokiol \| Grazoprevir \| Artemisinin \| EIDD-1931 \| Deferiprone \| Ribavirin \| HCV-IN-29 \| Sofosbuvir
相关库	经典已知活性库 \| 已知活性化合物库 \| EMA 上市药物库 \| FDA上市及药典收录分子库 \| NO PAINS 化合物库 \| 抗COVID-19化合物库 \| 抗病毒库 \| FDA 上市药物库 \| 药物功能重定位化合物库 \| 人代谢物化合物库

BW1263W94|||马立巴韦|||GW257406X|||Benzimidavir|||1263W94|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子